| 1. |
Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet, 2021, 397(10272): 428-444.
|
| 2. |
Roa JC, García P, Kapoor VK, et al. Gallbladder cancer. Nat Rev Dis Primers, 2022, 8(1): 69. doi: 10.1038/s41572-022-00398-y.
|
| 3. |
Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol, 2020, 72(1): 95-103.
|
| 4. |
殷曉煜, 許瓊聰. 膽囊癌手術治療的現狀與進展. 臨床肝膽病雜志, 2024, 40(12): 2366-2370.
|
| 5. |
Lei S, Huang G, Li X, et al. Global burden, trends, and inequalities of gallbladder and biliary tract cancer, 1990–2021: a decomposition and age-period-cohort analysis. Liver Int, 2025, 45(2): e16199. doi: 10.1111/liv.16199.
|
| 6. |
GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet, 2024, 403(10440): 2133-2161.
|
| 7. |
Jiang Z, Jiang Q, Wang P, et al. Gallbladder and biliary tract cancer burdens in China from 1990 to 2021 and projection to 2044: findings from the 2021 Global Burden of Disease study. Front Med (Lausanne), 2025, 12: 1592621. doi: 10.3389/fmed.2025.1592621.
|
| 8. |
劉書畫. 2000–2019年全球膽囊和膽管疾病的負擔分析. 贛州: 贛南醫學院, 2022.
|
| 9. |
李全美, 鄭西特, 黃鳳儀, 等. 1990–2019年中國消化系統惡性腫瘤發病與死亡趨勢分析和預測. 中華腫瘤防治雜志, 2025, 32(5): 259-266.
|
| 10. |
李丹妮, 張陽奕, 趙琦, 等. 基于GBD數據分析1990–2021年全球結核病護理質量指數的差異.浙江湖州: 第35屆中國防癆協會全國學術大會暨第四屆中國防癆科技頒獎大會, 2024: 453-454.
|
| 11. |
Mohammadi E, Ghasemi E, Azadnajafabad S, et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of brain and other central nervous system cancers; global burden of disease systematic analysis 1990–2017. PLoS One, 2021, 16(2): e0247120. doi: 10.1186/s40164-021-00198-2.
|
| 12. |
GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease study 2023. Lancet, 2025, 406(10513): 1873-1922.
|
| 13. |
陶偉, 徐兵. 1990–2023年中國胰腺炎疾病負擔及護理質量指數的趨勢分析. 中國普外基礎與臨床雜志, 2026, 33(4): 493-502.
|
| 14. |
Bi Y, Huang K, Wang M, et al. Global, regional and national burden and quality of care index (QCI) of leukaemia and brain and central nervous system tumours in children and adolescents aged 0–19 years: a systematic analysis of the Global Burden of Disease study 1990–2019. BMJ Open, 2025, 15(3): e093397. doi: 10.1136/bmjopen-2024-093397.
|
| 15. |
Murray C. Findings from the Global Burden of Disease study 2021. Lancet, 2024, 403(10440): 2259-2262.
|
| 16. |
韓宇浩, 吳茜, 彭金碧, 等. 廣東省職業性塵肺病ARIMA模型預測. 中國職業醫學, 2023, 50(2): 150-154.
|
| 17. |
Wu S, Zhao R, Zhuang Q, et al. Disease burden of primary gallbladder and biliary tract cancers associated with body mass index in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. J Dig Dis, 2022, 23(3): 157-165.
|
| 18. |
郭偉, 李鑫, 王明達, 等. 《腫瘤外科學年鑒: 肝外膽管癌和膽囊癌臨床診療指南》推薦意見. 臨床肝膽病雜志, 2024, 40(4): 682-687.
|
| 19. |
中華醫學會外科學分會膽道外科學組, 中國醫師協會外科醫師分會膽道外科專家工作組. 膽道惡性腫瘤全程規范化管理中國專家共識(2023). 中華外科雜志, 2024, 62(6): 504-513.
|
| 20. |
韓朝, 郭棟, 梁剛, 等. HMGB1和KLF7在膽囊癌組織中的表達及其與膽囊癌患者根治術后預后的關系. 肝膽胰外科雜志, 2026, 38(4): 247-254.
|
| 21. |
Zhan Z, Chen B, Teng W, et al. Trends and projections of gallbladder and biliary tract cancer in China: a comprehensive analysis from 1990 to 2030 based on the Global Burden of Disease study 2021. BMC Public Health, 2025, 25(1): 2409. doi: 10.1186/s12889-025-23601-7.
|
| 22. |
Hu Z, Wang X, Zhang X, et al. An analysis of the global burden of gallbladder and biliary tract cancer attributable to high BMI in 204 countries and territories: 1990–2021. Front Nutr, 2024, 11: 1521770. doi: 10.3389/fnut.2024.1521770.
|
| 23. |
劉珊山, 李初誼, 鄭英, 等. 1990–2019年中國膽囊癌疾病負擔研究及未來趨勢分析. 中國全科醫學, 2024, 27(14): 1742-1749.
|
| 24. |
Xie C, Shi D, Lin H, et al. Spatial patterns of gallbladder and biliary tract carcinoma in China from 1990 to 2019: an analysis at the provincial level. Cureus, 2023, 15(8): e42796. doi: 10.7759/cureus.42796.
|
| 25. |
Khanali J, Malekpour MR, Azangou-Khyavy M, et al. Global, regional, and national quality of care of gallbladder and biliary tract cancer: a systematic analysis for the global burden of disease study 1990–2017. Int J Equity Health, 2021, 20(1): 259. doi: 10.1186/s12939-021-01596-y.
|
| 26. |
鞠金宏, 盧賀峰, 周楊. MRI多序列掃描判定原發性膽囊癌組織病理學分期效能研究. 實用肝臟病雜志, 2026, 29(1): 157-160.
|
| 27. |
張英, 曹亞娟, 李劍. 黃色肉芽腫性膽囊炎的CT、MRI征象及診斷分析. 中國CT和MRI雜志, 2026, 24(1): 111-113.
|
| 28. |
潘韡, 陳燕凌. 膽囊癌外科治療的現狀與進展: 手術策略、輔助治療的選擇. 福建醫科大學學報, 2025, 59(5): 277-286.
|
| 29. |
陳超, 崔賓, 馬強強, 等. 腹腔鏡下膽囊癌根治術研究現狀. 中外醫學研究, 2025, 23(6): 160-163.
|
| 30. |
梁后杰, 秦叔逵, 沈鋒, 等. CSCO膽道系統腫瘤診斷治療專家共識(2019年版). 浙江創傷外科, 2019, 24(9): 828-838.
|
| 31. |
Burris HA 3rd, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2024, 25(5): 626-635.Burris HA 3rd, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2024, 25(5): 626-635.
|
| 32. |
李霓, 李江, 陳萬青, 等. 癌癥篩查指南及共識質量評價研究進展. 中華流行病學雜志, 2021, 42(02): 211-214.
|
| 33. |
陳萬青, 李霓, 石菊芳, 等. 中國城市癌癥早診早治項目進展. 中國腫瘤, 2019, 28(1): 23-25.
|
| 34. |
王玉玨, 聶萌, 徐依朋, 等. 腫瘤早篩早診與監測標志物. 中國科學基金, 2025, 39(1): 80-90.
|
| 35. |
Nooijen LE, van der Snee L, Ten Haaft B, et al. A critical appraisal of the potential benefit of post-operative structured follow-up after resection for biliary tract cancer. HPB (Oxford), 2024, 26(2): 179-187.
|
| 36. |
Rizzo A, Carloni R, Frega G, et al. Intensive follow-up program and oncological outcomes of biliary tract cancer patients after curative-intent surgery: a twenty-year experience in a single tertiary medical center. Curr Oncol, 2022, 29(7): 5084-5090.
|
| 37. |
Sandell T, Schütze H. Factors influencing the translation of shared cancer follow-up care into clinical practice: a systematic review. BMJ Open, 2022, 12(8): e055460. doi: 10.1136/bmjopen-2021-055460.
|
| 38. |
Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 2023, 34(2): 127-140.
|
| 39. |
王存生, 周樹理, 張晉崗, 等. 腹腔鏡膽囊切除術意外膽囊癌113例臨床分析. 實用醫技雜志, 2018, 25(10): 1147-1148.
|